<code id='A25DC00590'></code><style id='A25DC00590'></style>
    • <acronym id='A25DC00590'></acronym>
      <center id='A25DC00590'><center id='A25DC00590'><tfoot id='A25DC00590'></tfoot></center><abbr id='A25DC00590'><dir id='A25DC00590'><tfoot id='A25DC00590'></tfoot><noframes id='A25DC00590'>

    • <optgroup id='A25DC00590'><strike id='A25DC00590'><sup id='A25DC00590'></sup></strike><code id='A25DC00590'></code></optgroup>
        1. <b id='A25DC00590'><label id='A25DC00590'><select id='A25DC00590'><dt id='A25DC00590'><span id='A25DC00590'></span></dt></select></label></b><u id='A25DC00590'></u>
          <i id='A25DC00590'><strike id='A25DC00590'><tt id='A25DC00590'><pre id='A25DC00590'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          explore

          author:fashion    - browse:9
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge